What Innoviva, Inc. does.

Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets.

Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR ® /BREO ® ELLIPTA ® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO ® ELLIPTA ® (umeclidinium bromide/vilanterol, “UMEC/VI”). Under the Long-Acting Beta-2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO ® ELLIPTA ® , which tier upward at a range from 6.5% to 10%.

Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:

Revenue and profit, by fiscal year.

More on INVA.

• Innoviva, Inc. summary
• Innoviva, Inc. financial statements
• Innoviva, Inc. key metrics
• Innoviva, Inc. health scores and style box
• Innoviva, Inc. earnings
• Innoviva, Inc. dividends
• Innoviva, Inc. valuation
• Innoviva, Inc. ownership and insiders
• Innoviva, Inc. peers

Figures from Innoviva, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.